Yet, the number of patients was restricted considerably because no prior systemic therapy for advanced/metastatic disease was allowed, other than EGFR TKIs, and in some countries, chemotherapy was often used due to delays in EGFR TKIs authorizations by the Health Insurance Houses during 2015–2017. This evidence concerns the gene EGFR and metastatic neoplasm.